Last updated: 11/06/2018 23:37:39
Anti-Parkinson Efficacy of Ropinirole (SKF 101468) versus Placebo as Monotherapy in Parkinson's Disease
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Anti-Parkinson Efficacy of Ropinirole (SKF 101468) versus Placebo as Monotherapy in Parkinson's Disease
Trial description: Anti-Parkinson Efficacy of Ropinirole (SKF 101468) versus Placebo as Monotherapy in Parkinson's Disease
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Brooks DJ, Abbott RJ, Lees AJ et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21: 101-107
Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45 (suppl): 231-238
Rascol O. Anti Parkinson efficacy of ropinirole vs placebo as early therapy in Parkinson's disease. International Symposium on Parkinson's Disease, Rome, Italy, Mar 26-30, 1994. New Trends Clin Neuropharmacol 1994; 8: 279
Medical condition
Parkinson Disease
Product
ropinirole
Collaborators
Not applicable
Study date(s)
June 1990 to October 1991
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1991-31-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website